Table 5 Mean ± standard deviation VASI score for vitiligo type and lesion location at the 2-month follow-up after the discontinuation of treatment compared among the placebo, monotherapy, and combination therapy groups (ITT analysis).

From: The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study

Type and location

n

Placebo

Bimatoprost 0.01% monotherapy

Bimatoprost

0.01% + NBUVB

p*

Type of vitiligo

 Non-segmental type

13

90.77 ± 15.4

73.85 ± 23.3

52.69 ± 29.3

 < 0.001b

 Segmental type

6

83.33 ± 39.4

69.17 ± 33.8

60.00 ± 26.5

0.496

Location of lesion

 Face and neck

8

78.13 ± 32.7

72.50 ± 24.3

53.13 ± 20.9

0.230

 Other areas

11

95.91 ± 8.0

72.27 ± 28.6

56.36 ± 33.1

 < 0.001b

  1. A p-value < 0.05 indicates statistical significance.
  2. VASI score Vitiligo Area Scoring Index score, NBUVB narrowband ultraviolet B phototherapy, ITT intention to treat.
  3. *Repeated measures analysis of variance (ANOVA) with multiple comparisons by Bonferroni method.
  4. aPlacebo vs. monotherapy.
  5. bPlacebo vs. combination therapy.
Back to article page